Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05749055 · ClinicalTrials.gov registry record · Phase 2
ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder
A Phase 2 study, sponsored by Engrail Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
NCT05749055: Completed Phase 2 study, sponsored by Engrail Therapeutics.
NCT05749055 is a Phase 2 study that has completed, run by Engrail Therapeutics. The registered enrollment target is 252 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05749055, a Phase 2 study, has completed, sponsored by Engrail Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
Study Summary
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Primary Outcome
Mean change from baseline on the Hamilton Anxiety Rating Scale (HAM-A) total score \[14 symptoms with each symptom scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56 and higher scores representing worse outcomes\]
Interventions
- DRUG Placebo
- DRUG ENX-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2025-09-18 |
| Phase | Phase 2 |
What the finished NCT05749055 record still lists
NCT05749055 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05749055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05749055 about?
NCT05749055 is a clinical study titled "ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder". The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
What is the current status of trial NCT05749055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2023-07-03. Estimated completion is 2025-09-18.
What interventions are being tested in trial NCT05749055?
The interventions under investigation include: Placebo (DRUG), ENX-102 (DRUG).
Who is sponsoring clinical trial NCT05749055?
This trial is sponsored by Engrail Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05749055's enrollment target sits among peer trials
252 220th of 2000 higher than 1,779 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI